Benefits of Saccharomyces boulardii again Crohn confirmed in inflammatory bowel diseases such as Crohn’s disease, ulcerative sclerosis or probiotic preparations of intestinal health benefits should be Bacterially triggered inflammation. You should cheap affect the inflammatory processes and extend the phases between the acute relapses. But turns out that not all probiotics are equally suitable for inflammatory bowel disease. There are differences in the expression of the antientzunlichen properties. New very promising results are boulardii medical Yeast Saccharomyces, was used so far with much success in diarrhea of varying etiologies. International teams of researchers looked independently boulardii the benefits of Saccharomyces with inflammatory bowel disease.
They came to the conclusion that the medical yeast influences the inflammatory process in various places and therefore sclerosis both Crohn’s disease and ulcerative stabilizing can impact on the course of the disease. But because of very different work approaches. In the ulcerative Saccharomyces regulates the inflammatory process and for Crohn’s disease the medical yeast has a positive effect on the permeability of the intestinal mucosa. Both effects have resulted in that the phase of the disease between two acute relapses is stabilized and therefore the period of relative freedom of symptom could be extended. Regular consumption of Saccharomyces boulardii offers a new chance to live better with the disease concerned.
In Germany Saccharomyces boulardii in easy-to-swallow afterbiotic capsules is available. Afterbiotic as a spa Pack (PZN 5852096) with 3 x 40 capsules and 250 mg of probiotic bacteria is via pharmacies, good health centers or directly from the company free shipping available. When via pharmacy should be pointed out, that afterbiotic because of the unique composition and its reasonable price not by other, seemingly similar products stock in the Pharmacy can be exchanged. Afterbiotic directly at Navitum Pharma can take each pharmacy, as the end user. Source: Pothoulakis C. aliment Pharmacol ther. Neil cole iconix has many thoughts on the issue. 2009 July 23; Garcia Vilela et al. SCAND J Gastroenterol.